Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
Open Access
- 18 February 2021
- journal article
- review article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 11 (2) , 1-13
Abstract
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the ‘efficacy’ of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual’s composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting.Keywords
Funding Information
- Takeda Pharmaceuticals U.S.A.
This publication has 103 references indexed in Scilit:
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsHaematologica, 2013
- Content Development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): Use of Qualitative and Quantitative Methods for Scale ConstructionJournal of Pain and Symptom Management, 2012
- Physician, Patient, and Contextual Factors Affecting Treatment Decisions in Older Adults With Cancer and Models of Decision Making: A Literature ReviewOncology Nursing Forum, 2011
- Management of treatment-emergent peripheral neuropathy in multiple myelomaLeukemia, 2011
- Deriving a Preference-Based Measure for Cancer Using the EORTC QLQ-C30Value in Health, 2011
- Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myelomaThe European Journal of Health Economics, 2010
- Health related quality of life in a nationally representative sample of haematological patientsEuropean Journal of Haematology, 2009
- Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myelomaEuropean Journal of Haematology, 2008
- Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysisJournal of Clinical Epidemiology, 2007
- Health‐related quality of life assessed before and during chemotherapy predicts for survival in multiple myelomaBritish Journal of Haematology, 1997